Kyoto University · Medicine
Professor Tsubasa Watanabe's research lab specializes in translational oncology and molecular theranostics, with a focus on boron neutron capture therapy (BNCT) and targeted cancer therapies. The lab investigates the pharmacokinetics and biodistribution of boron compounds like BPA and FBPA in tumor and normal tissues, aiming to improve dose accuracy in BNCT through advanced imaging techniques such as PET. Additionally, the lab explores the synthesis and biological evaluation of natural product-derived anticancer agents, including irciniastatin A analogues, to understand structure-activity relationships and mechanisms of action. The team also contributes to the clinical management of rare brain tumors, such as pineal parenchymal tumors of intermediate differentiation, and investigates combination therapies involving radiotherapy and immunotherapy to enhance systemic antitumor responses.
Figures are computed from collected data and may differ slightly.
No difference was noted in the time course of the boron concentrations in tumour tissue and normal tissues between L-BPA and [<sup>19</sup>F]-L-FBPA. However, the administration protocol had effects on the normal tissue to blood ratio of the boron concentration. In estimating the BNCT dose in normal tissue by positron emission tomography (PET), we should consider the possible overestimation of the normal tissue to blood ratio of the boron concentrations derived from the values measured by PET on
Syntheses of both natural (+)- and unnatural (-)-irciniastatin A (aka psymberin) as well as a C1-C2 alkyne analogue of (+)-irciniastatin A have been achieved. The key features of the syntheses include a highly regioselective epoxide-opening reaction and a late-stage assembly of C1-C6, C8-C16, and C17-C25 fragments. (+)-Alkymberin retained a high level of cytotoxicity, whereas (-)-irciniastatin A showed almost no activity. These results suggest that (+)-alkymberin could be a useful enantio-differ
Boron neutron capture therapy (BNCT) is a binary cancer therapy that involves boron administration and neutron irradiation. The nuclear reaction caused by the interaction of boron atom and neutron produces heavy particles with highly cytocidal effects and destruct tumor cells, which uptake the boron drug. p-Boronophenylalanine (BPA), an amino acid derivative, is used in BNCT. Tumor cells with increased nutrient requirements take up more BPA than normal tissues via the enhanced expression of LAT1
Pineal parenchymal tumor of intermediate differentiation (PPTID) is a rare disease, first classified by the World Health Organization in 2000. The number of available studies on the treatment of PPTID is currrently limited and the optimal management for this disease has not yet been determined. We retrospectively evaluated the treatment outcomes for PPTID at our institute and analyzed the roles of radiation therapy and chemotherapy for this disease. The clinical data on five patients diagnosed w
Our findings may serve as a rationale for the clinical evaluation of this triple-combination therapy in patients with solitary or oligometastatic tumors in the neoadjuvant or the definitive setting.
Radiotherapy can elicit abscopal effects in non-irradiated metastases, particularly under immune checkpoint blockade (ICB). We report on two elderly patients with oligometastatic melanoma treated with anti-PD-1 and stereotactic body radiation therapy (SBRT). Before treatment, patient 1 showed strong tumor infiltration with exhausted CD8+ T cells and high expression of T cell-attracting chemokines. This patient rapidly mounted a complete response, now ongoing for more than 4.5 years. Patient 2 ex
Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive and malignant tumor that predominantly affects young males. No standard therapy is currently available for patients with DSRCT and the prognosis remains extremely poor. In this study, we report a thought-provoking DSRCT case. A 24-year-old male was admitted to our hospital with a chief complaint of hematemesis. Computed tomography revealed a retrovesical mass with a splenic hilar tumor, multiple lung and liver tumors and marked ly
Watanabe, Tsubasa MD; Tsuji, Yoshihisa MD, PhD; Kodama, Yuzo MD, PhD; Isoda, Hiroyoshi MD, PhD; Yamamoto, Hiroshi MD; Chiba, Tsutomu MD, PhD Author Information
Watanabe, Tsubasa MD; Tsuji, Yoshihisa MD, PhD; Takahashi, Naoki MD; Yoshida, Tsukasa MD; Tamaoki, Masashi MD; Kikuchi, Osamu MD; Watanabe, Yuji MD, PhD; Kodama, Yuzo MD, PhD; Isoda, Hiroyoshi MD, PhD; Yamamoto, Hiroshi MD; Chiba, Tsutomu MD, PhD Author Information
Abstract Nous avons déterminé les directions du moment de transition des quelques composés organiques, à la température ambiante, par le mesure d'absorption spectrale des composés à I'aide de la lumière polarisée, à I'état dissous dans le p-méthoxybenzylidéne-p-n-butytaniline un cristal liquide nématique, orienté par le traitement mécanique. Nous avons d'autre part constaté que cette méthode est trés utilisable pour la détermination du paramètre d'ordre d'orientation de la phase nématique. Dans
Open papers in the app to read, cite, and organize with AI.
